相似文献
1
BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.
Vaccines (Basel). 2020 Dec 4;8(4):736. doi: 10.3390/vaccines8040736.
2
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13853-8. doi: 10.1073/pnas.250480397.
3
Past, Present and Future of Bacillus Calmette-Guérin Vaccine Use in China.
Vaccines (Basel). 2022 Jul 20;10(7):1157. doi: 10.3390/vaccines10071157.
4
Protection against tuberculosis by Bacillus Calmette-Guérin (BCG) vaccination: A historical perspective.
Med. 2022 Jan 14;3(1):6-24. doi: 10.1016/j.medj.2021.11.006. Epub 2021 Dec 31.
5
Next-Generation Vaccines Based on Bacille Calmette-Guérin.
Front Immunol. 2018 Feb 5;9:121. doi: 10.3389/fimmu.2018.00121. eCollection 2018.
6
Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
Expert Rev Vaccines. 2007 Aug;6(4):539-46. doi: 10.1586/14760584.6.4.539.
7
Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.
Immunology. 2014 Oct;143(2):277-86. doi: 10.1111/imm.12308.
8
Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.
Tuberc Res Treat. 2011;2011:574591. doi: 10.1155/2011/574591. Epub 2011 May 24.
9
The impact of human single nucleotide polymorphisms on Bacillus Calmette-Guérin responses.
Vaccine. 2020 Sep 11;38(40):6224-6235. doi: 10.1016/j.vaccine.2020.07.032. Epub 2020 Aug 18.
10
Vaccines against Tuberculosis: Where Are We Now?
Vaccines (Basel). 2023 May 22;11(5):1013. doi: 10.3390/vaccines11051013.
引用本文的文献
1
Exploring BCG to deliver avidin fusion antigens from Schistosoma mansoni.
Mem Inst Oswaldo Cruz. 2025 Mar 3;120:e240167. doi: 10.1590/0074-02760240167. eCollection 2025.
2
BCG as immunostimulating agent prevents the severe form of chronic experimental Chagas disease.
Front Immunol. 2024 Mar 21;15:1380049. doi: 10.3389/fimmu.2024.1380049. eCollection 2024.
3
Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response.
Br J Cancer. 2023 Sep;129(4):572-585. doi: 10.1038/s41416-023-02327-6. Epub 2023 Jun 24.
4
Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics.
Vaccines (Basel). 2022 May 21;10(5):816. doi: 10.3390/vaccines10050816.
5
Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.
Viruses. 2022 Mar 3;14(3):520. doi: 10.3390/v14030520.
6
BCG immunotherapy inhibits cancer progression by promoting the M1 macrophage differentiation of THP‑1 cells via the Rb/E2F1 pathway in cervical carcinoma.
Oncol Rep. 2021 Nov;46(5). doi: 10.3892/or.2021.8196. Epub 2021 Sep 28.
7
Adjuvants and Antigen-Delivery Systems for Subunit Vaccines against Tuberculosis.
Vaccines (Basel). 2021 Aug 30;9(9):972. doi: 10.3390/vaccines9090972.
8
Recombinant Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections.
Front Immunol. 2021 Aug 27;12:712274. doi: 10.3389/fimmu.2021.712274. eCollection 2021.
9
Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain BCG SL222 Sofia.
Vaccines (Basel). 2021 Mar 9;9(3):237. doi: 10.3390/vaccines9030237.
10
Immunological Characterization of Proteins Expressed by Genes Located in -Specific Genomic Regions Encoding the ESAT6-like Proteins.
Vaccines (Basel). 2021 Jan 7;9(1):27. doi: 10.3390/vaccines9010027.
本文引用的文献
1
Association between live childhood vaccines and COVID-19 outcomes: a national-level analysis.
Epidemiol Infect. 2021 Mar 16;149:e75. doi: 10.1017/S0950268821000571.
2
Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis?
Bioessays. 2021 Mar;43(3):e2000200. doi: 10.1002/bies.202000200. Epub 2020 Nov 9.
3
Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries.
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:202-203. doi: 10.1016/j.cegh.2020.08.015. Epub 2020 Sep 5.
4
The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature.
Przegl Epidemiol. 2020;74(2):290-302. doi: 10.32394/pe.74.22.
5
Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses.
Sci Rep. 2020 Oct 27;10(1):18377. doi: 10.1038/s41598-020-75491-x.
6
An Overview of the Development of New Vaccines for Tuberculosis.
Vaccines (Basel). 2020 Oct 5;8(4):586. doi: 10.3390/vaccines8040586.
7
New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?
Cell Immunol. 2020 Oct;356:104187. doi: 10.1016/j.cellimm.2020.104187. Epub 2020 Jul 28.
8
Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.
Clin Exp Immunol. 2020 Sep;201(3):306-316. doi: 10.1111/cei.13469. Epub 2020 Jul 6.
9
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.
Oncoimmunology. 2020 Apr 21;9(1):1748981. doi: 10.1080/2162402X.2020.1748981. eCollection 2020.
10
BCG: a vaccine with multiple faces.
Hum Vaccin Immunother. 2020 Aug 2;16(8):1841-1850. doi: 10.1080/21645515.2019.1706930. Epub 2020 Jan 29.
Zotero 插件